
The Practice of Medicinal Chemistry
Camille Georges Wermuth(Editor)
Academic Press
2nd Edition
Published on 11. June 2003
Book
Hardback
736 pages
978-0-12-744481-9 (ISBN)
Article exhausted; check for reprint
Description
The Practice of Medicinal Chemistry, 2E, is a single-volume source on the practical aspects of medicinal chemistry. The successful first edition was nicknamed "The Bible" by medicinal chemists, and the second edition has been updated, expanded and refocused to reflect developments over the last decade. Emphasis is put on how medicinal chemists conduct their search for and design of new drug entities. In contrast to competing books, it focuses on the chemistry rather than pharmacological concepts or descriptions of the various therapeutic classes of drugs. Most medicinal chemists working in the pharmaceutical industry are organic synthetic chemists who must acquire a strong knowledge of medicinal chemistry as they enter the industry. This book aims to be their practical handbook - a complete guide to the drug discovery process.
Reviews / Votes
PRAISE FOR THE FIRST EDITION"...a useful, authoritative discussion of the principles and practice of medicinal chemistry...the volume has a useful index, is well produced, and is very resonably priced..." --JOURNAL OF MEDICINAL CHEMISTRY
More details
Edition
2nd edition
Language
English
Place of publication
San Diego
United States
Publishing group
Elsevier Science Publishing Co Inc
Target group
Professional and scholarly
Academic and industrial organic chemists / pharmacologists beginning a career in drug research, established scientists teaching medicinal chemistry, graduate and post-graduate medicinal chemists, biochemists, physical chemists, structural biologists, protein chemists, molecular biologists, and researchers and scientists in the pharmaceutical industry.
Edition type
New edition
Dimensions
Height: 276 mm
Width: 216 mm
Weight
2590 gr
ISBN-13
978-0-12-744481-9 (9780127444819)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions

Camille Georges Wermuth | David Aldous | Pierre Raboisson
The Practice of Medicinal Chemistry
Book
07/2015
4th Edition
Academic Press
€138.50
Shipment within 15-20 days

Camille Georges Wermuth
The Practice of Medicinal Chemistry
Book
07/2008
3rd Edition
Academic Press
€188.17
Article exhausted; check for reprint
Additional editions

Camille Georges Wermuth
The Practice of Medicinal Chemistry
E-Book
06/2003
2nd Edition
Academic Press
€195.00
Available for download
Previous edition
Camille Georges Wermuth
The Practice of Medicinal Chemistry
Book
02/1996
Academic Press
€167.13
Article exhausted; check for reprint
Person
Camille-Georges Wermuth PhD, Prof. and Founder of Prestwick Chemical, was Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France from 1969 to 2002. He became interested in Medicinal Chemistry during his two years of military service in the French Navy at the "Centre d'Etudes Physio-biologiques Appliquees a la Marine" in Toulon. During this time he worked under the supervision of Dr Henri Laborit, the scientist who invented artificial hibernation and discovered chlorpromazine.
Professor Wermuths' main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome.
Dr. Wermuth is co-author or editor of several books, the author of over 250 scientific papers and holds nearly 60 patents. Professor Wermuth is also the recipient of the Charles Mentzer Prize of the Societe Francaise de Chimie Therapeutique, the Leon Velluz Prize of the French Academy of Science, the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy and the Nauta Award of the European Federation for Medicinal Chemistry for Pharmacochemistry in 2010.
Professor Wermuths' main research themes focus on the chemistry and the pharmacology of pyridazine derivatives. The 3-aminopyridazine pharmacophore, in particular, allowed him to accede to an impressive variety of biological activities, including antidepressant and anticonvulsant molecules; inhibitors of enzymes such as mono-amine-oxidases, phosphodiesterases and acetylcholinesterase; ligands for neuro-receptors: GABA-A receptor antagonists, serotonine 5-HT3 receptor antagonists, dopaminergic and muscarinic agonists. More recently, in collaboration with the scientists of the Sanofi Company, he developed potent antagonists of the 41 amino-acid neuropeptide CRF (corticotrophin-releasing factor) which regulates the release of ACTH and thus the synthesis of corticoids in the adrenal glands. Professor Wermuth has also, in collaboration with Professor Jean-Charles Schwartz and Doctor Pierre Sokoloff (INSERM, Paris), developed selective ligands of the newly discovered dopamine D3 receptor. After a three-year exploratory phase, this research has led to nanomolar partial agonists which may prove useful in the treatment of the cocaine-withdrawal syndrome.
Dr. Wermuth is co-author or editor of several books, the author of over 250 scientific papers and holds nearly 60 patents. Professor Wermuth is also the recipient of the Charles Mentzer Prize of the Societe Francaise de Chimie Therapeutique, the Leon Velluz Prize of the French Academy of Science, the Prix de l'Ordre des Pharmaciens by the French Academy of Pharmacy and the Nauta Award of the European Federation for Medicinal Chemistry for Pharmacochemistry in 2010.
Editor
Professor of Organic Chemistry and Medicinal Chemistry at the Faculty of Pharmacy, Louis Pasteur University, Strasbourg, France
Content
Drug Targets
Natural Products
Electronic Screening
Identical and Non-Identical Twin Drugs
Optical Isomerism in Drugs and more
Natural Products
Electronic Screening
Identical and Non-Identical Twin Drugs
Optical Isomerism in Drugs and more